Structural-functional features of NG2/CSPG4
===========================================

NG2/CSPG4 is a unique, multivalent transmembrane proteoglycan (PG) accountable for many of the interactions taking place between cancer cells and their microenvironment to promote the myriad of cellular events propagating tumour growth and spreading (**Fig. [1](#F1){ref-type="fig"}**; [@B1]-[@B5]). It was originally identified on the surface of cutaneous melanoma cells, as part of a repertoire of immune-dominant antigens characteristic of these neoplastic cells [@B6]-[@B11], and because of its large size was named *High Molecular Weight Melanoma-Associated Antigen* (HMW-MAA or simply *Melanoma Cell Surface Proteoglycan* - MCSP). Coincidently, the same molecule was disclosed to be implicated in neuron-glial interactions in the rodent CNS and was accordingly named Neuron-Glia Protein 2 (NG2;[@B12]). Following cloning of the rodent orthologue [@B13], the human NG2 gene (CSPG4; [@B14]) was pinpointed to chromosome 15:24q2 [@B15] and shown to encode for a 8.9 kb transcript with an open reading frame of 8,071 nucleotides which translates into a core protein of 2,322 residues. This polypeptide encompasses numerous glycosylation sites and three putative glycosaminoglycan (GAG)-attachment sites, yielding the potential to generate a molecule of \>500 kDa. Owing to its extended extracellular domain, NG2/CSPG4 has the potential to engage in a multitude of molecular interactions, spanning from sequestration of growth factors, signalling molecules and metalloproteinases to binding to cell surface receptors for these ligands and to the ECM (**Fig. [1](#F1){ref-type="fig"}**).

In highly motile cells, such as cancer cells, NG2/CSPG4 accumulates in the advancing cytoplasmic front, in filopodial extensions and at cell-substratum contact areas (**Fig. [1](#F1){ref-type="fig"}**). Extracellular cleavage of the molecule contributes to both the physiological and disease-associated fragmentation of the extracellular domain by a cell-autonomous signal transduction-dependent mechanism. Tryptic products of the PG have been widely described [@B16], [@B17], but these ectodomain fragments still lack a precise homeostatic or pathological function. There is similarly remarkably scanty information about the glycosylation/glycanation patterns of NG2/CSPG4 molecules expressed by healthy and cancer tissues and how these may be related to the PG\'s structural-functional diversities. The cytoplasmic tail of NG2/CSPG4 contains two threonine residues undergoing differential phosphorylation by PKCα (Thr^2256^) and ERK(s) (Thr^2314^) depending upon the cellular events in which the PG may participate [@B18], [@B19]. Through PDZ-type adaptor proteins, such as MUPP1 and synthenin-1, the intracellular domain of NG2/CSPG4 links to the actin cytoskeleton, in part also via a close association with ezrin and cofilin-1. These cytoskeletal connections and the above mentioned PKC/ERK-regulated threonine phosphorylations activate a number of signalling effectors including FAK, PI-3K, Akt1, Rac1, cdc42, Ack1 and p130^CAS^ [@B18]-[@B24]. The inter-relationship between NG2/CSPG4 and these signal transducers and its functional implication is gradually being resolved.

Tissue distribution of NG2/CSPG4 is wider than that originally thought, but still prevails on discrete premature cells prone to originate tumours
=================================================================================================================================================

It was originally suggested that the expression pattern of NG2/CSPG4 was restricted to a limited number of tissues, with a certain prevalence for the CNS and "immature cell phenotypes" [@B25]-[@B27]. With the advent of more specific reagents to capable of detecting the PG in situ, its expression has progressively been documented in a larger proportion of human tissues, where it seems to be proper of cell types not necessarily representing the most immature ones of that given tissue/anatomical district. According to information retrievable from the literature, from publicly accessible data bases, and from our own immune-mapping studies, NG2/CSPG4 is highly expressed in \>10 tissues/organs of the adult human body (brain, gastrointestinal tract, endocrine organs), but, remarkably, in many of these tissue/organs there is an enigmatic poor correlation between transcript and protein levels. Despite its fairly wide expression pattern (\>50 cell types), in most anatomical sites, NG2/CSPG4 appears indeed characteristic of precursor/progenitor cells, including putative stem/progenitor cells of both epithelial and mesodermal origin [@B28]-[@B39].

Upregulation of NG2/CSPG4 is a frequent event of neoplastic progression, but its diagnostic utility is clinically overlooked - why is that?
===========================================================================================================================================

There is currently no information on amplifications of chromosome 15:24q [@B40], or any other genetic anomaly (e.g. chromosomal translocation, gene deletion, exon skipping, etc) involving the NG2/CSPG4 gene and/or causing alterations in the expression of the PG in diseased cells. Analogously, NG2/CSPG4 has not been identified as a factor directly promoting tumour formation, but has been shown to become de novo expressed in a number of solid and haematological neoplastic conditions, as well as to be linked to cancer-associated epithelial-mesenchymal transitions [@B3]. The most striking examples of this latter transitional linkage are the appearance of NG2/CSPG4 on melanoma cells, breast, head and neck carcinomas and mesotheliomas ([@B41]-[@B43]; Rossi et al., *submitted)*. Conversely, in mesenchymal tumours the relationship between NG2/CSPG4 expression and neoplastic transformation is different: NG2/CSPG4 is constitutive of the mesenchymal progenitor/stem cells [@B35], [@B39] from which sarcomas are thought to originate [@B44] and becomes progressively upregulated with increasing malignancy [@B24], [@B45]. The remarkable inter-patient and intra-lesional variability in de novo expression/upregulation of NG2/CSPG4 remains puzzling and has not found a clear explanation. Similarly, it remains to be uncovered to what extent the functions exerted by NG2/CSPG4 on healthy and cancer cells actually coincide.

Even though high transcriptional levels of the CSPG4 gene may be detected, appearance of PG on the surface of cancer cells may not always occur (i.e. the PG is primary detected intracellularly) and is likely to be a mere *secondary* event of tumour formation. It may therefore not be entirely unexpected to obtain confounding results from studies on autochthonous murine cancer models. For instance, experimentally induced cerebral tumours, i.e. elicited by ectopic expression of the PDGF proto-oncogene in the developing mouse brain [@B46], [@B47], have been observed to form equally well in the total absence of NG2/CSPG4 [@B48]. Somewhat unpredictable was, however, the discovery that, in spite of the well-documented role of NG2/CSPG4 in PDGF signalling [@B29], [@B49]-[@B52], PDGF-induced gliomas not only originated with the same frequency, but also progressed to the same extent in the NG2/CSPG4 null background as in wild type animals [@B48]. A clear-cut explanation for this apparent inconsistency has not yet been provided, but differences in experimental models and biological contexts within which the NG2/CSPG4 involvement in PDGF signalling has been documented may be the ground for the discrepancy. An alluring possibility may further be that the NG2/CSPG4 contribution to the cells\' responses to PDGF is dose-related: at optimal ratios of NG2/CSPG4 molecules versus available PDGF ligand in proximity of the cell surface, the PG exerts a precise co-receptor function. By contrast, when the growth factor molecules reaches the cell membrane at outnumbering amounts compared to the available NG2/CSPG4 surface molecules, then the co-receptor role of the PG is strongly attenuated, or even bypassed. Such scenario would be coherent with a discrete docking receptor function of NG2/CSPG4, acting within the framework of the "absolute model" of morphogen gradient-perception [@B53], as we have recently underscored for the involvement of NG2/CSPG4 in FGF signalling [@B52].

Gene profiling data accrued during the years and a wide spectrum of immunochemical studies, have thoroughly substantiated the enhanced expression of NG2/CSPG4 in several cancer types (**Table [1](#T1){ref-type="table"}; Fig. [2](#F2){ref-type="fig"}**). At present, augmented transcriptional and/or translational levels of NG2/CSPG4 have been disclosed in 34 solid tumour types (and their subvariants) [@B8], [@B41]-[@B43], [@B45], [@B54]-[@B73], and, in several of them, a certain diagnostic and/or prognostic connotation of the PG has been proposed (**Table [1](#T1){ref-type="table"}; Fig. [3](#F3){ref-type="fig"}**). A wealth of studies have additionally indicated the potential value of NG2/CSPG4 (alone or in combination with other antigens) in disclosing occult and/or micro-metastases by histology and diagnostic whole-body imaging [@B74]-[@B82]. Meanwhile, corollary investigations have underscored the usefulness of the PG as a marker for circulating cancer cells in melanoma patients (**Fig. [2](#F2){ref-type="fig"}**; [@B83]-[@B89]); a similar potential is expectable for other solid tumours exhibiting abundant NG2/CSPG4 expression levels.

Notably, in several solid tumours, NG2/CSPG4 is more abundant and more homogeneously distributed in metastatic lesions than in the primary tumour masses [@B24], [@B43], [@B45], [@B57], [@B59], [@B67], [@B68], [@B90]. This would suggest that the PG may drive metastasis formation, as proposed by some experimental data in the mouse [@B42], [@B70], [@B91]-[@B93]. Obviously, it is technically impossible to determine whether NG2/CSPG4 overexpressing cells of primary lesions actually are the ones fated to give rise to metastases, because of a destiny imparted by the action of NG2/CSPG4, or whether malignant cells forming metastases simply upregulate the PG site-specifically. In this latter case, upregulation of NG2/CSPG4 should be considered to be a *tertiary* tumorigenic event, whose significance remains to be investigated. A comprehensive picture of the relative distribution and frequency of NG2/CSPG4-expressing subpopulations of cells constituting primary versus secondary lesions also remains to be determined, leaving thereby unresolved to what extent NG2/CSPG4-enriched cancer cell subsets may influence metastasis formation. Furthermore, although cells engineered to overexpress NG2/CSPG4 are generally more malignant than their counterpart NG2/CSPG4-deficient cells [@B42], [@B43], [@B91], [@B92], unequivocal experimental proof of a direct metastasis-promoting effect of the PG is currently missing. It is, however, interesting to note that enhanced expression of NG2/CSPG4 in primary lesions of oral cavity carcinomas strongly predicts tumour recurrence (Rossi et al., *submitted*; **Table [1](#T1){ref-type="table"})**. This adds to the *theranostic* value of the PG, as it identifies a patient subgroup that may benefit from an NG2/CSPG4-targeted therapeutic approach.

Given its documented diagnostic impact, it appears perplexing that NG2/CSPG4 has remained largely unutilized as a biomarker for the routine clinical monitoring of cancer patients. This may be due to the failure of most of the published studies to demonstrate the independence of dysregulated NG2/CSPG4 expression from established clinical parameters. One of the few exceptions may be our recent discovery in soft-tissue sarcomas; there, relative levels of expression of the PG in pulmonary metastatic lesions identifies a patient subgroup with an independently predicted adverse disease course (**Table [1](#T1){ref-type="table"}**; [@B24], [@B45]). As a clinically applicable adjunct, NG2/CSPG4 overexpression in primary lesions of soft-tissue sarcoma patients predicts the development of post-surgery metastases in these individuals within an average period of 12 months post-surgery and does so with the striking probability of about 65% [@B24]. In addition, there is evidence that enhanced NG2/CSPG4 expression in soft-tissue sarcoma and chordoma patients affects their response rate to combined radiation and chemotherapy, thereby stratifying responders versus non-responders and further underscoring the *theranostic* impact of the PG.

Dismally fated leukemic patients de novo express NG2/CSPG4, down-stream of MLL rearrangements, to develop drug resistance
=========================================================================================================================

Curiously, the strategy adopted for producing monoclonal antibodies against key cell surface antigens that originally led to the unfolding of NG2/CSPG4 in melanoma was reproduced on hematopoietic malignancies ten years later with same result: a unique antibody against NG2/CSPG4 was generated [@B94], [@B95]. The use of monoclonal antibody 7.1 obtained from this approach revealed the unexpected ectopic expression of NG2/CSPG4 on neoplastic cells from a subset (**Table [2](#T2){ref-type="table"}**) of fate-compromised children suffering from acute myeloid leukemia (AML). By contrast, the PG was not found on normal T- and B-lymphocytes, monocytes, granulocytes, bone marrow hematopoietic stem/progenitor cells, platelets or red blood cells. The majority of AML patients (\>75%), whose neoplastic cells were found to express NG2/CSPG4, exhibited FAB-M4/M5 leukemic blasts carrying MLL gene rearrangements located on chromosome band 11q23. These cells exhibited a poorly differentiated (CD4^+^, CD7^+^), CD56^+^ myelomonocytic immunophenotype [@B94], [@B96]-[@B98], suggesting that NG2/CSPG4 expression strongly correlated with a stage maturation arrest.

A series of subsequent studies concurred on the fact that \>60% of the leukemic cases with MLL rearrangements display NG2/CSPG4 cell surface expression, while, if reversed, high expression of the PG coincided in 80-100% of the cases with gene rearrangements (**Table [2](#T2){ref-type="table"}**). Therefore, the consensus is that de novo expression of NG2/CSPG4 tightly correlates with 11q23-associated genetic abnormalities and identifies a specific and well-defined subset of leukemic patients with a putative unfavourable prognosis. Pioneering investigations on infants affected by acute lymphoblastic leukemia (ALL) similarly identified subgroups of patients whose leukemic cells de novo expressed NG2/CSPG4 in association with t(11;19)(q23;p13), t(4;11)(q21;q23) and t(9;11)(q21;q23) translocations [@B95], [@B98], [@B99]. These original findings were tightly corroborated by computational, quantitative and quantitative flow cytometry analyses performed on 1,461 infants with B-ALL. Thanks to these investigations,although NG2/CSPG4 expression was restricted to a subgroup of patients presenting MLL rearrangements, we can theoretically suppose that all patients with NG2/CSPG4-positive leukemic blasts could have coincident MLL rearrangements [@B100], i.e. NG2/CSPG4 expression was asserted to be "diagnostic" of MLL gene aberrations. Furthermore, the linkage between induced NG2/CSPG4 expression and MLL gene alterations is not limited to childhood leukemia, but is also seen in adult ALL patients. In this case, the NG2/CSPG4-expressing phenotype is a typical precursor B-cell, displaying the CD10^-^/CD13^-^/CD15^+^/CD22^+^/CD24^-^/CD33^-^/CD65s^+^/CD117 phenotype, a variable expression of CD19 and CD34, and absence of leukemic stem cell traits [@B98], [@B101]-[@B103].

Collectively, the above investigations on acute leukemia affirm a stringent correlation between MLL rearrangements, rare variants with often peculiar cell phenotypes [@B104], and ectopic expression of NG2/CSPG4. However, they leave veiled several biological and clinical questions, including the biological significance of the NG2/CSPG4 expression on discrete leukemic cells and the therapeutic potential of this selective expression. The negative outcome of the experimental targeting of a model leukemic cell line with two anti-NG2/CSPG4 antibodies [@B105], independently validated as effective tools for abrogating growth and dissemination of solid tumour xenografts (*see below*), reinforces these uncertainties. In parallel, in a recent publication Petrovici et al. [@B106], reported some AML cases manifesting a normal karyotype, while, concurrently, a significant amount of the leukemic cells expressed NG2/CSPG4. This finding together with the frequency of NG2/CSPG4 expression on plasmacytoid dendritic leukemia cell lines lacking MLL abnormalities and having the immunophenotype CD34^+^/CD38^+^/CD45^+^/CD123^+^/HLADR^+^ [@B107] have led investigators to draw an important conclusion: in the absence of MLL rearrangements, expression of the PG on leukemic cells may be dictated by the context within which leukemogenesis is initiated [@B108]. Since no other onco-hematological disease has presently been disclosed to involve misexpression of NG2/CSPG4, the unprecedented surface display in hematopoietic cells (else than macrophages and brain microglia) appears to be a facultative leukemogenesis-specific event.

Additional unresolved issues of the leukemia-NG2/CSPG4 linkage are: whether ectopic/enhanced expression of the PG electively correlates with a specific MLL rearrangement? Whether transcription/translation of the PG is a direct consequence of such genetic anomaly? Currently published data do not support a specific link between NG2/CSPG4 surface expression and a specific MLL rearrangement, while many works support the conjecture that such gene rearrangements may trigger the ectopic surface appearance of the PG. In fact, we have recently found that transduction of the MF4 fusion product into leukemic cells, not harboring this genetic aberration, activates NG2/CSPG4 gene transcription and surface display of the PG \[*unpublished*\]. We also find that induced NG2/CSPG4 expression in leukemic MLL rearranged cells confer to them a generalized drug resistance manifested by up-regulation of several drug transporters \[*unpublished*\]. Thus, enhanced NG2/CSPG4 expression in leukemic cells may promote their aggressiveness in a cell-autonomous manner and thereby contribute to the dismal clinical course of these patients.

NG2/CSPG4 may pair with cancer initiating cell subsets
======================================================

Despite its reportedly unfavourable prognostic connotation, the presence of NG2/CSPG4 on AML cells having a CD34^-^/CD38^+^ phenotype is claimed to be incompatible with an elective expression of the PG on candidate leukemic stem cells \[i.e. the PG may either be present or not on such cells; [@B102]. However, this claim is based upon examination of only 6 leukemic cases, calling upon more in depth analyses to firmly establish the identity of the NG2/CSPG4-presenting leukemic cells. In cerebral and oral cavity tumours, experimental evidence also would seem to confute a strict correspondence between putative stem cells and highly malignant NG2/CSPG4-expressing cells ([@B69], [@B109]-[@B111]; Rossi et al.,*submitted*). However, in gliomas [@B69], [@B110], [@B112], soft-tissue sarcomas [@B24], oral cavity carcinomas (Rossi et al., *submitted*), breast carcinoma [@B42] and mesothelioma [@B43] NG2/CSPG4 is found on average on \<50% of the cells composing the tumour lesion and, in most cases, these cells seem to harbor tumour initiating properties. Accordingly, immunotargeting of CD20-NG2/CSPG4-expressing melanoma cell subsets in animal models eradicates the predominant portion of the tumour [@B113].

Heterogeneity of intra-lesional NG2/CSPG4 expression hence corroborates the idea that the PG pertains to aggressive cancer cell subsets, albeit no correlation studies have yet been published to clarify whether the average number of NG2/CSPG4 positive cells within a primary or secondary tumour lesion discriminates patient subgroups with a diverse clinical course. Nevertheless, the exacerbated malignant properties of NG2/CSPG4-expressing cancer cell populations ([@B3], [@B24], [@B94], [@B110]; Nicolosi et al., *in preparation*) co-expressing markers of immature cell types strongly favors the notion that, at least in solid tumours, NG2/CSPG4 may be associated with cancer stem/cancer initiating cells [@B42]. In addition, we have recently observed that subpopulations of glioblatoma cells display NG2/CSPG4 variants immunologically distinct from those found on normal and tumorigenic perivascular cells and developing glial cell progenitors [@B112]. This finding highlights a remarkable structural variability of NG2/CSPG4 in cerebral cancers and points to the potential of targeting selective neoplastic cells of these tumours, which may correspond to cancer initiating cells, with isoform-specific antibodies.

Insights into the putative function of NG2/CSPG4 in cancer inception and progression gained from tumorigenesis studies in animal models
=======================================================================================================================================

More than 40 different cancer cell lines constitutively expressing high levels of NG2/CSPG4, or transduced to ectopically express the PG, display enhanced aggressiveness in syngenic or xenogenic transplantation settings. Moreover, we have recently shown that the magnitude of local growth of xenografted sarcoma cells is largely proportional to the relative levels of NG2/CSPG4 on their surfaces ([@B24]; Nicolosi et al., *in preparation*). Hence, these and numerous other investigations corroborate a widespread tumour-promoting activity of NG2/CSPG in solid tumours, which is exhibited by promotion of four cancer-related cellular phenomena: (I) survival in stressed conditions, (II) drug resistance, (III) intra-lesional neovascularisation, and (IV) metastatic ability (**Fig. [1](#F1){ref-type="fig"}**). Supportive findings from in vitro assays purport the concept that NG2/CSPG4 may affect drug sensitivity of cancer cells by reinforcing their interactions with the host microenvironment, especially with the stromal ECM, by modulating the activity of certain integrins and, through these actions, by activating pro-survival signalling cascades [@B22], [@B24], [@B114]-[@B116]. Conversely, NG2/CSPG4 does not seem to interfere with apoptosis or autophagy. It has been argued that the ability of NG2/CSPG4 to elicit signalling cascades involving the PI-3K-Akt-1-mTOR axis, possibly through an upstream activation of ERK and PKC-related pathways ([@B3], [@B18], [@B19], [@B22]-[@B24]; Cattaruzza et al., *unpublished*), is the key pro-survival mechanism operated by the PG. Phosphorylation of the cytoplasmic threonines of NG2/CSPG4 is likely to be an obligatory step for the co-activation of these cell survival-associated signalling events resulting from associations of the PG with the ECM [@B19], [@B24]. Recent indirect evidence for a significant role of NG2/CSPG4 in controlling responses to target therapy drugs stems from the ability of anti-NG2/CSPG4 antibodies to prolong the growth inhibitory effect of the BRAF^V600E^ inhibitor vemurafenib [@B117].

Exploitation of the NG2/CSPG4 knockout mouse alone, or in combination with PDGFRβ null mice, highlights another facet of the NG2/CSPG4 involvement in tumour progression. In a NG2/CSPG4-poor background, tumour growth and spreading is strongly impaired indicating that the PG is an essential component of the tumour microenvironment. Experimental evidence substantiating a tight association between the host PG and the formation of intra-lesional neovessels (**Fig. [3](#F3){ref-type="fig"}**) provides one conceivable explanation for how NG2/CSPG4 of the tumour microenvironment may influence cancer growth. The role of the PG in angiogenesis is bimodal as it involves a direct control of the behaviour of sprouting neovascular cells [@B62], [@B118]-[@B120] and the coincident sequestration of angiocrine factors [@B1], [@B51], [@B52], [@B121]. This latter event may in turn promote multivalent molecular interactions favouring the intimate interplays between pericytes, the endothelium and the tumour cells [@B112], [@B116], [@B120], [@B122], [@B123]. Accordingly, simulation of the neovascularisation process in vitro, growth factor-induced angiogenesis in the corneal experimental paradigm [@B52], [@B124], and subcutaneous cell-matrix transplantation approaches (e.g. so called "Matrigel plug" assays), consistently support the pivotal pericyte-linked function of NG2/CSPG4. Some of these experimental systems have additionally unveiled an unprecedented implication of the PG in the recruitment of tumour-infiltrating macrophages [@B125], while bringing to the attention the precocious contribution of resident and bone marrow-derived NG2/CSPG4-expressing pericytes to the angiogenic sprouting process [@B125]-[@B129].

Induced expression of NG2/CSPG4 in cells lacking the PG may accentuate their metastatic potential [@B43], [@B91], [@B130] and, accordantly, knockdown via RNAi of the endogenous PG represses local growth in primary tumour grafting models [@B69], [@B70]. These observations let hypothesize that a wealth of NG2/CSPG4 immunotargeting approaches forcefully could implicate the PG in cancer progression (**Table [3](#T3){ref-type="table"}**). Averted growth and dissemination of xenografted cancer cells has been documented in animals receiving anti-NG2/CSPG4 antibodies, when such have been employed in their naked canonical form, in their mono- and bivalent recombinant versions, or as conjugates with a variety of cytotoxic and/or pro-apoptotic agents. While the overwhelming majority of these studies have traditionally focused on melanoma [@B70], [@B91], [@B113], [@B119], [@B131]-[@B144], a number of other tumour types, such as mesothelioma [@B43],head neck squamous cell carcinoma [@B144], glioblastoma [@B22], [@B48], [@B69], [@B70], [@B120], [@B145]-[@B147] and breast carcinoma [@B42], [@B123], [@B141], [@B144] have recently emerged as equally targetable (**Table [3](#T3){ref-type="table"}**). In most instances of NG2/CSPG4 targeting through naked antibodies, the tumour-abrogation effect caused by the antibody treatments has been attributed to a decrease of FAK and ERK(-pathway) activation. However, since the cross-reactivity of these antibodies with the host murine NG2/CSPG4 orthologue was not determined and the precise basis for the reduced phosphorylations has not convincingly been addressed, it is uncertain whether dephosphorylation of the above signalling components was directly attributed to the antibody-cancer antigen reaction. Thus, although these findings solidly demonstrate the applicability of NG2/CSPG4 as an immunotherapeutic target, they leave veiled the modalities through which such a therapeutic approach should be coaxed to bring about an effective tumour eradication.

Direct immunotargeting of NG2/CSPG4 may latently arrest growth and dissemination of a variety of cancer cell types in different experimental settings, but a number of more indirect targeting approaches have also proven to generate the desired tumour-abrogating results (**Table [3](#T3){ref-type="table"}**). Chimeric anti-NG2/CSPG4 antibodies fused to superantigens [@B134], or to apoptosis-inducing receptor ligands (such as TRAIL; [@B138], and bi- [@B148] or tri-specific [@B149] antibodies simultaneously targeting ancillary antigens) effectively reduce tumour burden in mice. More recently, bispecific antibodies constructed such as to bind both NG2/CSPG4 and the lymphocyte receptor CD3 and allowing redirection of the cytotoxic activity of T lymphocytes toward melanoma cells \[so called "BiTi technology"; [@B66], [@B150], [@B151] have been exploited to engender NG2/CSPG4-mediated immune attack of cancer cells. These investigations and other studies reinforce the innate NG2/CSPG4 immunodominant properties, manifested by the CTL-4 responses that the PG seems to evoke against the tumour cells and the induction of auto-antibodies against specific epitopes of NG2/CSPG4 in the absence of a generalized autoimmunity [@B152]-[@B155]. Anti-tumour (primarily melanoma) immunereactions may also be elicited by NG2/CSPG4 mimotopes [@B137], [@B156], [@B157], suggesting that the PG encompasses strongly (auto-)immunogenic sequences capable of priming dendritic and/or immune cells upon their pathological activation (i.e. in the context of inflammatory conditions as those ruling in cancer patients). However, mimotopes found to be capable of inducing anti-NG2/CSPG4 immune responses do not match with the N-terminal peptide found to be recognized by CD4^+^ T cells in both healthy individuals and melanoma patients and presumed to correspond to a self-tolerant sequence of the PG [@B154], [@B155].

How far are we from the adoption of NG2/CSPG4 as a clinically accepted therapeutic target?
==========================================================================================

Despite the lack of broader mechanistic insights, the success rate of anti-NG2/CSPG4 immunological agents affords a solid pre-clinical rationale for attempting the eradication of different tumour types through NG2/CSPG4 targeting. However, an obvious caveat with these pre-clinical studies is that they have been performed in xenogenic settings with putative human NG2/CSPG4-specific antibodies. This leaves uncertain the possible side effects that these immunological agents may have on healthy cells, especially on the numerous PG-expressing progenitor cells (including perivascular ones), and the extent to which these agents may affect homeostatic phenomena such as wound healing and tissue regeneration. On the other hand, a concurrent NG2/CSPG4-directed attack of malignant cancer cells and the pericyte subsets driving tumour angiogenesis is generally believed to be an attractive double-targeting approach. If striving at using NG2/CSPG4 as a preferred target for tumour abrogation, one way of circumventing disturbing collateral effects may be the elective targeting of cell type-specific glycoforms of the PG ([@B112]; Dallatomasina et al., *in preparation*). In addition, we have observed an extensive nucleotide and amino acid polymorphism of NG2/CSPG4 in tumour cell lines and in circulating cancer cells of soft-tissue sarcoma patients (Dallatomasina et al., *in preparation*). Collectively, these recent findings highlight the potential to utilize anti-NG2/CSPG4 immunological reagents with finer antigen specificity than those previously exploited such as to target discrete and well-defined cancer cell subsets.

Off-target effects that might incidentally be encountered when attempting a direct pan-immune-targeting of NG2/CSPG4, may analogously be obtained when exploring active immunotherapeutic approaches based upon immunization of patients with anti-idiotypic antibodies [@B158]-[@B161]. Nevertheless, documented clinical benefits of NG2/CSPG4 anti-idiotypic antibody treatment of cancer patients has led to the ranking of the PG within the 100 most effective tumour markers for vaccination approaches on cancer patients [@B162]. Effectiveness of NG2/CSPG4-directed immunization strategies were originally suggested by clinical studies entailing vaccination of advanced melanoma patients with the anti-idiotypic antibody MK2-23, which mimics a 15 amino acid sequence within the NG2/CSPG4 recognized by antibody 763.74 [@B163]. Treatment of more than 80 patients with mAb MK2-23, alone or when conjugated to immunogenicity enhancers, was found to reduce the sizes of metastatic lesions and to significantly prolong patient survival, presumably by eliciting a multitude of humoral immunological responses that could span from T cell-mediated production of anti-anti-idiotypic antibodies to the endogenous production of antibodies directed against NG2/CSPG4 [@B164]-[@B166]. Regression analyses consistently demonstrated that induction of antibodies against NG2/CSPG4 were the primary correlate with extended patient survival and strongly suggested that re-evoked and/or augmented levels of anti-NG2/CSPG4 auto-antibodies were the bases for the observed curing effects.

The approximately 50% success rate observed in these inceptive clinical studies has incited a more extended Phase II trial performed at CRO National Cancer Institute Aviano (Italy) on over 100 advanced melanoma patients who were selected for the high NG2/CSPG4 expression in the primary lesions and lack of brain metastases. These individuals were subjected to prolonged vaccination regimens with mAb MK2-23, alone or in combination with adjuvant IL-2 or GMS-F administration. The striking outcome of this study was that, when evaluated within a follow-up period of more than 10 years, an unexpected 12% of patients manifested complete disease remission and about another 20% experienced a stall of the disease (M. Maio, *personal communication*). Again, the observed clinically tangible effects markedly correlated with high serum levels of anti-NG2/CSPG4 antibodies and alloreactive T lymphocytes. Passive and active NG2/CSPG4 immunotargeting approaches are therefore believed to harbor the potential to intervene in the progression of the numerous tumour types discovered to overexpress the PG. These approaches may effectively be paralleled by approaches relying upon antibody dependent cytotoxicity in which isoform-specific anti-NG2/CSPG4 antibodies may be employed to ameliorate the targeting specificity.
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![Schematic portrayal of the involvement of NG2/CSPG4 in biological phenomena known to be pivotal in the regulation of tumour growth and spreading. There is solid experimental evidence for a primary role of NG2/CSPG4 in mediating the tumour cells\' interactions with their microenvironmental ECM. Through its capability to sequester various growth factors and modulate the activity of their cognate receptors, NG2/CSPG4 directly controls cancer cell proliferation (*upper panel*). Cells overexpressing NG2/CSPG4 up-regulate signalling pathways associated with cell survival (i.e. the PI-3K-mTOR-Akt1-PTEN axis) and attain a pronounced resistance to both conventional and target therapy drugs, as as well to radiation therapy (*middle upper panel*). NG2/CSPG4 is a primary pericyte marker and it acts as a primary regulator of angiogenesis. In fact, it serves as a mediator of pericyte activation and thereby as a promoter of angiogenic sprouting (*lower middle panel*). Its ability to interact with ECM, alongside with the ability to modulate the activity of multiple integrins and metalloproteinases, allow NG2/CSPG4 to be tightly implicated in the control of cancer cell movement and invasion. This includes the entrance and exit of disseminating cancer cells from the haematic and lymphatic circuits (*lower panel*).](thnov05p0530g001){#F1}

![NG2/CSPG4 isoforms are strongly expressed in a variety of tumour types and are effectively exploitable for the identification of circulating cancer cells. (**A-H**) Examples of NG2/CSPG isoform distribution in selected tumour types known to frequently express high levels of the PG, as provided by immunostainings with propriety monoclonal antibodies and a Human Protein Atlas polyclonal antiserum: high grade cutaneous melanoma (**A**); ductal breast carcinoma (**B**, adapted and reprinted with permission from [@B71], courtesy Dr. M-F. Huo); adenocarcinoma of stomach (**C**); colorectal adenocarcinoma (**D**); chordoma (**E**; courtesy Dr. E. Tamborini); malignant glioblastoma (**F**, adapted and reprinted with permission from [@B112], courtesy Drs Francesco Girolamo and Daniela Virgintino); lung metastasis of synovial sarcoma (**G**); and uterine leiomyosarcoma double stained with propriety monoclonal antibodies detecting cancer cell-associated versus pericyte-elective isoforms (**H**). (**I)** Detection of circulating cancer cells isolated from a patient with advanced melanoma through CD146-conjugated ferrofluid beads and enumerated and phenotyped by fluorescently labelled anti-CD34/CD45 and anti-NG2/CSPG4 antibodies (adapted and reprinted with permission from [@B86], courtesy Dr. L.W.M.M. Terstappen).](thnov05p0530g002){#F2}

![Potential of NG2/CSPG4 as a prognostic biomarker. (**A**) Assessment of the relative NG2/CSPG4 transcript levels in primary versus pulmonary metastatic lesions (the two types of lesions derived from the same individual) in soft-tissue sarcoma patients (n=86) affected by leiomyosarcoma, fibrosarcoma, liposarcoma, pleomorphic sarcoma or synovial sarcoma. A significantly (*p*\<0.003; univariate analysis) enhanced NG2/CSPG4 mRNA expression is detectable in metastatic formations (we have previously reported analogous data; [@B45], [@B52]). "*Healthy tissue*" corresponds to the surgical resection margins of the primary lesions. (**B**) Overall survival rates in soft-tissue sarcoma patients expressing higher (n=65) or lower (n=43) levels of NG2/CSPG4 mRNA in their lung metastases, following standard radiation and chemotherapy treatment and showing a significantly more favorable clinical course in patients with lower NG2/CSPG4 mRNA levels (*p*\<0.03 by univariate analysis; Benassi, Pazzaglia and Perris, *unpublished*). (**C**) Overall survival rates of breast carcinoma patients expressing high levels of NG2/CSPG4, as determined by immunolabeling, when compared to patients with lower levels (n= 240). Even if more modestly, clinical outcome was significantly less dismal (*p*=0.193; univariate analysis) in patients with low NG2/CSPG4 levels (derived and adapted with permission from [@B71]; courtesy Dr. M.-F. Hou).](thnov05p0530g003){#F3}

![Implication of NG2/CSPG4 in tumour angiogenesis, as evidence in a virally induced mouse model of mammary carcinoma (MMTV-PyMT; derived and adapted with permission from [@B123], courtesy Dr. W.B. Stallcup) . (**A-D**) Primary (*P*) and secondary (*N*) lesions (including lymphnodal infiltration; "*L*") induced in wild type (**A, B**) and NG2/CSPG4 null mice (**C, D**), as shown by Carmine alum staining of mammary glands in the two genotypes. (**E-H**) Extension of the neovascular network developed in carcinoma lesions arising in wild type (**E, F**) and NG2/CSPG4 null (**G, H**) mice (endothelial and pericyte markers, CD31 and αSMA, respectively).](thnov05p0530g004){#F4}

###### 

Diagnostic-prognostic implications of NG2/CSPG4 expression in solid tumours^1^

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumour type^2^                             Primary^2^   Metastasis   Prognosis                        Transcript^3^         Protein (antibody)^4^                                                          Reference
  ------------------------------------------ ------------ ------------ -------------------------------- --------------------- ------------------------------------------------------------------------------ -----------------------------------------------
  **Soft tissue sarcomas**                                                                                                                                                                                   

  Fibrosarcoma                               100%         100%         OS, MetP                         qPCR                  IHC, Ab D2                                                                     [@B24], [@B46]

  Leiomyosarcoma^5^                          100%         100%         OS, MetP                         qPCR                  IHC, Ab D2                                                                     [@B24], [@B46]

  Pleomorphic                                100%         100%         OS, MetP                         qPCR                  IHC, Ab D2                                                                     [@B24], [@B46]

  Liposarcoma^6^                             100%         100%         OS, MetP                         qPCR                  IHC, Ab D2                                                                     [@B24], [@B46]

  Synovial                                   100%         100%         OS, MetP                         qPCR                  IHC, Ab D2                                                                     [@B24], [@B46]

  Chondrosarcoma                             48%          Unknown      Unknown                          qPCR                  IHC, mAbs 63.74, VF1-TP41.2, VT80.12                                           [@B66]

  **Cerebral tumours**                                                                                                                                                                                       

  Glioblastoma                               20-100%      Unknown      DP, OS                           qPCR,\                IHC, FACS,WB, Ab D2; mAbs 9.2.27, N143, N109, N92                              [@B1], [@B57], [@B61], [@B62], [@B70], [@B71]
                                                                                                        whole-genome arrays                                                                                  

  **Bone tumours**                                                                                                                                                                                           

  Chordoma                                   62%          Unknown      Unknown                          qPCR                  IHC, mAbs 763.74, VF1-TP41.2, VT80.12                                          [@B66]

  **Breast carcinomas**                                                                                                                                                                                      

  TNBC                                       73%          86%          Unknown                          Data base^7^          IHC, mAb 225.28                                                                [@B43]

  ER+                                        40%          Unknown      Unknown                          Data base             IHC, mAb 225.28                                                                [@B43]

  HER2+                                      17%          Unknown      Unknown                          Data base             IHC, mAb 225.28                                                                [@B43]

  Lobular                                    67%          Unknown      PFS                              \--                   IHC, mAb 225.28S                                                               [@B65]

  Ductal                                     3%           Unknown      Unknown                          \--                   IHC, mAb 225.28S                                                               [@B65]

  ER^+^, HER2^+^, PR^+^, TNBC                14.5-66.2%   47.7%        TR (not TNBC), OS                \--                   IHC, mAb 83508                                                                 [@B72]

  **Squamous cell carcinoma**                                                                                                                                                                                

  Oral cavity                                100%         Unknown      Unknown                          \--                   IHC, mAb 9.2.27                                                                [@B42]

  **Pancreatic tumors**                                                                                                                                                                                      

  cystadenoma                                100%         \--          diagnostic but not prognostic\   qPCR                  IHC,WB, Ab LHM2,\                                                              [@B167]
                                                                       relevance.                                             Ab H-300                                                                       

  intraductal papillary mucinous neoplasms   100%         100%         diagnostic but not prognostic\   qPCR                  IHC,WB, Ab LHM2,\                                                              [@B167]
                                                                       relevance.                                             Ab H-300                                                                       

  Ductal malignancies                        100%         100%         diagnostic but not prognostic\   qPCR                  IHC,WB, Ab LHM2,\                                                              [@B167]
                                                                       relevance.                                             Ab H-300                                                                       

  **Melanoma**                                                                                                                                                                                               

  Uveal                                      69%          Unknown      Unknown                          \--                   IHC, mAb 9.2.27                                                                [@B64]

  NS                                         46-100%      81-100%      Unknown                          \--                   FACS, IHC, mAbs 225.28, 225.28S, 149.53;763.74T, 763.74, VF1-TP41.2, VT80.12   [@B8], [@B56], [@B65], [@B67]

  Acral lentiginous                          21-54%       82%          OS, PFS                          \--                   IHC, mAbs D2.8.5-C4B8, 225.28, TP41.2, TP61.5                                  [@B58], [@B60], [@B68]

  Nodular                                    100%         92%          Unknown                          \--                   IHC, mAbs 225.28, TP41.2, TP61.5                                               [@B58]

  Superficial spreading                      100%         Unknown      Unknown                          \--                   IHC, mAb D2.8.5-C4B8                                                           [@B68]

  Conjunctival                               100%         100%         OS, MetP                         \--                   IHC, mAb LHM2                                                                  [@B69]

  Desmoplastic                               95%          87%          MetP                             qPCR                  IHC, mAbs\                                                                     [@B73]
                                                                                                                              763.74, VF1-TP41.2, VT80.12                                                    

  **Mesothelioma**                                                                                                                                                                                           

  Sarcomatoid                                100%         Unknown      Unknown                          \--                   IHC, mAb D2.8.5-C4B8                                                           [@B44]

  Epithelioid                                48%          Unknown      Unknown                          \--                   IHC, mAb D2.8.5-C4B8                                                           [@B44]

  Biphasic                                   100%         Unknown      Unknown                          \--                   IHC, mAb D2.8.5-C4B8                                                           [@B44]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Based upon studies reporting a minimum of 5 cases, including subvariants of the tumour;

^2^Frequency scoring, i.e. percentage of cases showing positivity out of the total analyzed;

^3^As determined by either gene expression profiling by DNA microarray or by real-time quantitative PCR (qPCR);

^4^As determined by immunohistochemistry (IHC) and/or Western blotting (WB; antibody clone code is indicated);

^5^Includes pleomorphic and conventional leiomyosarcomas;

^6^Includes myxoid, round-cell and pleomorphic liposarcoma variants;

^7^From publicly accessible datasets (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE5460>);

^8^NG2/CSPG4 has also been detected in sporadic cases of renal cell carcinoma, angiomyolipoma, astrocytoma, oligodendroglioma, atypical meningioma, pilocytic astrocytoma, medulloblastoma, ependimoma, but not conventional meningioma, gastric carcinoma, colon adenocarcinoma and neuroendocrine tumours [@B61]-[@B63], [@B65], [@B74], [@B74], [@B114]

*Abbreviations:* OS = overall survival, MetP = metastasis predicting; PFS = progression/disease free survival; DP = disease progression; TR: tumour recurrence; NS = not specified.

###### 

Diagnostic-prognostic implications of NG2/CSPG4 expression in hematological malignancies^1^

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Leukemia   Age group      NG2/CSPG4 positive cases^2^\   NG2/CSPG4 positivity *vs* prevalent FAB status/Phenotype\   NG2/CSPG4 positivity in MLL germline cases\   NG2/CSPG4 positivity in MLL rearranged cases\   Disease course   References
                            (out of *n*)                   of MLL rearranged cases                                     (out of *n*)                                  (out of *n*)                                                     
  ---------- -------------- ------------------------------ ----------------------------------------------------------- --------------------------------------------- ----------------------------------------------- ---------------- ------------
  ALL        Infant         9% (104)                       56% pro-B; 33% pre-B; 11% T-ALL                             0% (89)                                       100% (9)                                        ND               [@B96]

  AML        Infant         11% (166)                      67% M5                                                      0% (85)                                       78% (18)                                        Poor             [@B95]

  AML        Infant         35% (37)                       58% M4/M5                                                   0% (13)                                       54% (24)                                        Unaffected       [@B97]

  AML        Infant/Adult   43% (14)                       75% M5                                                      0% (25)                                       43% (14)                                        ND               [@B98]

  AML/\      Infant/Adult   14% (533)                      NS\                                                         2% (12)                                       81% (72)                                        ND               [@B99]
  ALL                                                      25% myeloid/NK cell ALL; 16% pro-/pre-B- ALL                                                                                                                               

  ALL        Adult          23% (313)                      78 pro-B, 11% pre-B                                         19% (48)                                      89% (72)                                        ND               [@B102]

  AML/\      Infant         82% (11)                       NS                                                          ND                                            100% (9)                                        Poor             [@B103]
  ALL                                                                                                                                                                                                                                 

  ALL        Adult          95% (184)                      100% pro-/pre-B                                             15% (66)                                      91% (118)                                       ND               [@B104]

  AML        Adult          23% (70)                       50% M5                                                      29% (62)                                      63% (8)                                         Poor             [@B107]

  AML/\      Infant         48% (311)                      NS\                                                         58% (143)                                     42% (143)                                       ND               [@B100]
  ALL                                                      90% pro-B, 6% T-ALL                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^As established by flow cytometry using the reference mAb 7.1;

^2^Adopted average cut-off was \>25% of leukemic blasts;

^3^NG2/CSPG4 expression has also been documented in one case of DC2/NK cell ALL [@B105];

*Abbreviations*: NS = not specified; ND = not determined.

###### 

Implication of NG2/CSPG4 in tumour progression as suggested by in vivo studies^1^

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumour type                             Cell line                    Host                             Targeting agent/\                                        Effect                                                                Reference
                                                                                                        experimental condition                                                                                                         
  --------------------------------------- ---------------------------- -------------------------------- -------------------------------------------------------- --------------------------------------------------------------------- -----------
  ***Xenogenic***                                                                                                                                                                                                                      

  Triple-negative breast carcinoma        MDA-MB-435^2^\               C.B17-SCID                       mAb 225.28                                               Reduced tumour volume;\                                               [@B43]
                                          MDA-MB-231                                                                                                             inhibition of metastasis formation; inhibition of tumour recurrence   

  Glioblastoma                            U87MG                        Athymic                          mAb 9.2.27-DAVLBHY^3^                                    Reduced tumour volume                                                 [@B146]

  Glioblastoma                            U87MG\                       Athymic                          mAb 9.2.27-*Pseudomonas* exotoxin A                      Increased survival                                                    [@B147]
                                          Glioblastoma biopsy                                                                                                                                                                          

  Glioblastoma                            U87MG\                       NOD-SCID                         TNFα                                                     Diminished drug resistance                                            [@B22]
                                          U87MG_shRNA^4^                                                                                                                                                                               

  Glioblastoma^5^                         U251\                        Athymic                          Ionizing radiation                                       Increased treatment resistance                                        [@B70]
                                          U251-NG2^+^                                                                                                                                                                                  

  Glioblastoma/\                          U251, U251-NG2\              Athymic (glioblastoma),\         NG2 shRNA                                                Reduced tumour volume; impaired angiogenesis                          [@B71]
  Melanoma                                Glioblastoma biopsy\         NOD-SCID (melanoma)                                                                                                                                             
                                          A375_shRNA^4^                                                                                                                                                                                

  Glioblastoma                            U251-NG2^+5^\                Athymic                          mAb 9.2.27 + NK cells                                    Increased survival                                                    [@B148]
                                          Glioblastoma biopsy, U87MG                                                                                                                                                                   

  Melanoma/\                              SENMA\                       NSG                              Redirected T cells\                                      Reduced tumour volume                                                 [@B145]
  Brest carcinoma/\                       UACC-812\                                                     with a CSPG4-specific (CAR) with CD28\                                                                                         
  Head and neck squamous cell carcinoma   PCI-30                                                        costimulatory endodomain                                                                                                       

  Melanoma                                M21                          Athymic                          mAb 9.2.27-*Diphtheria* toxin A                          Reduced tumour volume                                                 [@B132]

  Melanoma                                Colo38                       Athymic                          mAb 225.28S-Purothionin                                  Reduced tumour volume                                                 [@B133]

  Melanoma                                M21                          Athymic                          mAb 225.28-methotrexate                                  Reduced tumour volume                                                 [@B134]

  Melanoma                                FM3, FM55\                   NOD-SCID                         mAb K305-*Staphylococcal* enterotoxin A                  Redirection of T cells against cancer cells;\                         [@B135]
                                          FMEX, G361,\                                                                                                           reduced tumour volume                                                 
                                          Melanoma biopsy                                                                                                                                                                              

  Melanoma                                518A2                        NOD-SCID                         mAb 225.28                                               Reduced tumour volume                                                 [@B136]

  Melanoma                                MM138                        Athymic                          mAb 9.2.27-Bi^213^                                       Inhibition of tumor engraftment; delayed tumor growth                 [@B137]

  Melanoma                                518A2                        C.B.17 SCID/SCID                 NG2/CSPG4 mimotope 225D9.2+                              Reduced local growth                                                  [@B138]

  Melanoma                                MeWo\                        NIH-III Mice                     Redirected T cells\                                      Reduced tumour volume                                                 [@B114]
                                          Melanoma biopsy                                               with bispecific anti- NG2/CSPG4-CD20 mAbs                                                                                      

  Melanoma                                A375                         Athymic                          scFv 9.2.27-TRAIL                                        Reduced tumor volume                                                  [@B139]

  Melanoma                                MV3\                         NOD-SCID                         mAb scFv-FcC21                                           Reduced level of lung metastases;\                                    [@B140]
                                          M21                                                                                                                    increased survival                                                    

  Melanoma                                A375M                        NOD-SCID                         MV-FCU1-αHMWMAA + 5-FC^6^                                Reduced tumour volume                                                 [@B141]

  Mesothelioma                            PPM-Mill                     C.B.17 SCID/SCID                 mAb TP41.2                                               Reduced tumour volume                                                 [@B44]

  AML                                     ML-2                         NOD-SCID                         mAbs 225.28, 653.25;763.74, TP61.5, VT68.2               No effect                                                             [@B106]

  ***Syngenic and/or transgenic***                                                                                                                                                                                                     

  Breast carcinoma/\                      B16F10\                      C57BL/6\                         Immunization with\                                       Impaired angiogenesis;\                                               [@B142]
  Melanoma                                B16F10-NG2^+5^               NT-2\                            *Lm*-HMW-MAA-C^7^                                        reduced tumour volume                                                 
                                                                       FVB/N HER-2/*neu*                                                                                                                                               

  Breast carcinoma                        None                         MMTV-PyMT-NG2^-/-^               NG2/CSPG4^-/-^\                                          Delayed tumour formation; impaired angiogenesis                       [@B124]
                                                                                                        + virally induced tumors                                                                                                       

  Glioblastoma                            None                         C57BL/6-NG2^-/-^\                NG2/CSPG4^-/-^ or NG2/CSPG4 miRNA + ectopic PDGF-BB^8^   No effect                                                             [@B49]
                                                                       C57BL/6                                                                                                                                                         

  Glioblastoma/\                          B16F10-NG2^+5^, CT2A         C57Bl/6-NG2^-/-^                 NG2/CSPG4^-/-^                                           Delayed tumour growth                                                 [@B121]
  Melanoma                                                                                                                                                                                                                             

  Melanoma                                B16F10-NG2^+5^\              C57Bl/6                          NG2/CSPG4^-/-^                                           Increased tumour volume;\                                             [@B92]
                                          B16F1-NG2^+5^                                                                                                          increased metastasis formation                                        

  Melanoma                                OCM-1A                       C57BL/6-NG2^-/-^\                NG2/CSPG4^-/-^+ Cyclosporin A                            Impaired angiogenesis;\                                               [@B120]
                                                                       C57BL/6                                                                                   reduced tumor volume                                                  

  Melanoma                                B16F10                       C57BL/6-NG2^-/-^\                Ablation of pericyte NG2/CSPG4                           Impaired angiogenesis                                                 [@B143]
                                                                       C57BL/6-NG2^-/-^-PDGFRB-CRE^9^                                                                                                                                  

  Melanoma                                B16F10                       BALB/c mice                      TH10-DTX-NP^10^                                          Increased survival; impaired angiogenesis (lung metastases)           [@B144]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Reported findings refer to tumour models with constitutively high expression of NG2/CSPG4, cell lines with forced (over)expression of the PG and models of RNAi-mediated knockdown of NG2/CSPG4;

^2^The MDA-MB-435 cell line is recognized to be of melanoma origin and has been misquoted in Wang et al. 2010 [@B43];

^3^DAVLBHY = 4-desacetylvinblastine-3-carboxyhydrazide;

^4^Refers to cells stably transfected with a shRNA probe to induce persistent knockdown of NG2/CSPG4;

^5^Refers to studies in which glioblastoma cell lines were stably transfected to overexpress NG2/CSPG4;

^6^Oncolytic measles virus entering melanoma cells through NG2/CSPG4 and carrying FCU1 gene encoding the yeast-derived prodrug convertases cytosine deaminase and uracil phosphoribosyltransferase for the conversion of the prodrug 5-fluorocytosine into 5-fluorouracil;

^7^*Lm*-LLO-HMW-MAA-C = Recombinant *Lm(Listeria monocytogenes)*-based vaccine secreting a fragment of NG2/CSPG4 fused to LLO;

^8^Intra-uterus injection of PDGF-BB or NG2/CSPG4-directed miRNA into E14 embryonic brains;

^9^NG2/CSPG4 floxed mice and PDGFR-B-Cre transgenic mice were backcrossed to a C57Bl/6 background;

^10^TH10-DTX-NP = TH10 peptide (TAASGVRSMH) conjugated to docetaxel-loaded nanoparticles.
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